Production (Stage)
Cytophage Technologies Ltd.
CYTO.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.41M | -5.78M | -5.84M | -5.80M | -5.75M |
| Total Depreciation and Amortization | 561.70K | 516.30K | 520.70K | 475.30K | 431.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.30K | 1.99M | 2.19M | 2.23M | 2.60M |
| Change in Net Operating Assets | 374.80K | -233.80K | -262.40K | -277.80K | -254.20K |
| Cash from Operations | -2.44M | -3.50M | -3.39M | -3.38M | -2.98M |
| Capital Expenditure | -909.50K | -953.50K | -909.10K | -669.30K | -151.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -160.70K | 5.66M | 4.02M | 4.02M | 4.02M |
| Cash from Investing | -1.07M | 4.71M | 3.11M | 3.35M | 3.86M |
| Total Debt Issued | 225.00K | 225.00K | 25.00K | 25.00K | 25.00K |
| Total Debt Repaid | -222.10K | -261.10K | -379.90K | -345.60K | -283.00K |
| Issuance of Common Stock | 5.00K | 2.51M | 2.76M | 2.98M | 3.35M |
| Repurchase of Common Stock | -2.50M | -2.50M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.50M | -28.80K | -71.30K | -71.30K | -73.80K |
| Cash from Financing | 3.90K | -49.70K | 1.72M | 1.90M | 2.22M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.51M | 1.16M | 1.43M | 1.87M | 3.11M |